236 related articles for article (PubMed ID: 18048089)
1. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2008; 122(3):328-35. PubMed ID: 18048089
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
3. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers.
Rothenbacher D; Müller-Scholze S; Herder C; Koenig W; Kolb H
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):194-9. PubMed ID: 16239601
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
8. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
9. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
[TBL] [Abstract][Full Text] [Related]
10. Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
Peng Y; Liu H; Liu F; Ouyang L; Cheng M; Gao L; Pan F; Liu Y; Chen X; Li J
Nephrology (Carlton); 2008 Oct; 13(7):579-86. PubMed ID: 19161364
[TBL] [Abstract][Full Text] [Related]
11. Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media thickness in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2006; 26(5):497-502. PubMed ID: 17119331
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
13. Carotid atherosclerosis is associated with enhanced beta-chemokine levels in patients on continuous ambulatory peritoneal dialysis.
Pawlak K; Pawlak D; Brzosko S; Mysliwiec M
Atherosclerosis; 2006 May; 186(1):146-51. PubMed ID: 16099464
[TBL] [Abstract][Full Text] [Related]
14. Enhanced levels of urokinase plasminogen activator and its soluble receptor in common variable immunodeficiency.
Fevang B; Eugen-Olsen J; Yndestad A; Brosstad F; Beiske K; Aukrust P; Frøland SS
Clin Immunol; 2009 Jun; 131(3):438-46. PubMed ID: 19232508
[TBL] [Abstract][Full Text] [Related]
15. Blood urokinase plasminogen activator system in chronic urticaria.
Kasperska-Zajac A; Brzoza Z; Rogala B
Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
[TBL] [Abstract][Full Text] [Related]
16. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
18. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
19. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms.
Kraaijeveld AO; de Jager SC; de Jager WJ; Prakken BJ; McColl SR; Haspels I; Putter H; van Berkel TJ; Nagelkerken L; Jukema JW; Biessen EA
Circulation; 2007 Oct; 116(17):1931-41. PubMed ID: 17909104
[TBL] [Abstract][Full Text] [Related]
20. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
Wittenhagen P; Kronborg G; Weis N; Nielsen H; Obel N; Pedersen SS; Eugen-Olsen J
Clin Microbiol Infect; 2004 May; 10(5):409-15. PubMed ID: 15113317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
